Drugs / KW-136
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03416491 | Feb → Sep 2017 | chronic hepatitis C virus infection | Kawin Technology Share-holding Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03995485 | Jun 2017 → Jan 2018 | chronic hepatitis C virus infection | Kawin Technology Share-holding Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KW-136 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03416491 ↗ |
| Action | Inhibit | “KW-136, an investigational HCV NS5A inhibitor” NCT03995485 ↗ |
| Route | Oral | “all-oral” NCT03995485 ↗ |